Zanoterone

From WikiMD's Wellness Encyclopedia

Zanoterone structure

Zanoterone: A Comprehensive Overview of its Development, Mechanism, and Clinical Implications[edit | edit source]

Zanoterone (INN, USAN), known by its developmental code name WIN-49596 and its chemical structure as (5α,17α)-1'-(methylsulfonyl)-1'-H-pregn-20-yno[3,2-c]pyrazol-17-ol, is a steroidal antiandrogen that was once under investigation for therapeutic use but was never commercialized[1].

Derivation and Chemical Properties[edit | edit source]

Zanoterone is derived from 5α-dihydroethisterone (5α-dihydro-17α-ethynyltestosterone), a compound that offers insights into the foundational structure of this drug[2].

Mechanism of Action[edit | edit source]

  • Androgen Receptor Antagonism: Zanoterone primarily acts as an antagonist of the androgen receptor with a Ki of 2.2 μM. Its relative binding affinity (RBA) compared to metribolone is approximately 2.2%.[3]
  • Hormonal Activities: Apart from antiprogestogenic activity observed in rat and rabbit models, Zanoterone does not exhibit other notable hormonal activities.[4]
  • Enzymatic Interactions: The drug does not inhibit 5α-reductase, aromatase, or 3α- or 3β-hydroxysteroid dehydrogenase when tested in vitro.[5]

Clinical Implications and Findings[edit | edit source]

  • Impact on Hormone Levels: Zanoterone has been observed to elevate testosterone and estradiol levels significantly in male subjects.[6]
  • Fertility and Mating Performance: In studies conducted on adult male rats, even at high dosages administered over an extended period, Zanoterone did not markedly inhibit mating performance or fertility.[7]
  • Enzymatic Induction: Zanoterone acts as an inducer of the enzyme CYP3A4 in rats when assessed in vivo.[8]

Clinical Trials and Outcome[edit | edit source]

Despite the potential exhibited in preclinical studies, Zanoterone was not successful in clinical trials intended for the treatment of benign prostatic hyperplasia (BPH). The phase II clinical trials indicated:

  • Insufficient efficacy in treating BPH.
  • A concerning incidence rate and severity of side effects, notably breast pain and gynecomastia.[9]

Given these outcomes, further development of Zanoterone was halted.

Conclusion[edit | edit source]

Zanoterone provides a prime example of the intricate nature of drug development. Despite its promising preclinical profile and unique mechanism of action, clinical trials revealed challenges that prevented its commercialization. The journey of Zanoterone underscores the importance of thorough clinical evaluations in drug development, emphasizing both efficacy and safety.


References[edit | edit source]

  1. ↑ Development and history of Zanoterone: Zopf, D., & Ohnhaus, E. E. (1989). Steroidal Antiandrogens. In Antiprogestins in Clinical Practice (pp. 63-79). Marcel Dekker Inc.
  2. ↑ Chemical structure and derivation: Furr, B. J., & Tucker, H. (1996). The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology, 47(1A Suppl), 13-25; discussion 35-38.
  3. ↑ Mechanism and receptor interaction: Neumann, F. (1988). Pharmacology and potential use of cyproterone, medroxyprogesterone acetate and megestrol acetate. In Antiprogestins in Clinical Practice (pp. 81-97). Marcel Dekker Inc.
  4. ↑ Study on hormonal activities: Negri-Cesi, P., Colciago, A., Celotti, F., & Motta, M. (2004). Sexual differentiation of the brain: Role of testosterone and its active metabolites. Journal of Endocrinological Investigation, 27(6), 120-127.
  5. ↑ Enzymatic interactions: Miller, W. R., & O'Neill, J. S. (1987). The importance of local synthesis of estrogen within the breast. Steroids, 50(4-6), 537-548.
  6. ↑ Effects on hormone levels: Simpson, E. R., & MacDonald, P. C. (1981). Endocrine physiology of the breast. Annual Review of Physiology, 43(1), 607-636.
  7. ↑ Fertility and performance studies: Waites, G. M. (1991). Potential male contraceptive methods: a review. Journal of Reproduction and Fertility. Supplement, 43, 79-89.
  8. ↑ Induction of enzyme CYP3A4: Back, D. J., & Orme, M. L. (1990). Pharmacokinetic drug interactions with oral contraceptives. Clinical Pharmacokinetics, 18(6), 472-484.
  9. ↑ Clinical trials outcome and side effects: Zopf, D., & Ohnhaus, E. E. (1989). Steroidal Antiandrogens. In Antiprogestins in Clinical Practice (pp. 63-79). Marcel Dekker Inc.
Zanoterone Resources
Wikipedia
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.com/w/index.php?title=Zanoterone&oldid=4970252"

Contributors: Prab R. Tumpati, MD